Precision Oncology with Theragnostics, Radiopharmaceuticals, and Molecular Payloads

Theranostics, radiopharmaceuticals, and molecular payloads are revolutionizing precision oncology by providing more personalized approaches to the diagnosis and treatment of cancer. Advances in this multidisciplinary field now span a broad array of malignancies, including, but not limited to, gynecologic cancers, by integrating targeted imaging, molecularly specific payload delivery, and innovative therapeutic strategies.

This Research Topic seeks to gather pioneering research and expert insights on the ongoing clinical and preclinical evolution of theranostics, next-generation radiopharmaceuticals, antibody-drug conjugates, and other molecular payloads across all solid and hematologic tumors. Central themes include innovations in energy oncology, targeted radiation delivery, molecularly guided diagnosis, and the optimization of novel delivery mechanisms and combination regimens.

By welcoming studies that explore gynecologic, breast, prostate, gastrointestinal, thoracic, and other cancer types, we aim to foster a platform for comparative and comprehensive discussion, catalyze cross-discipline clinical translation, and highlight transformative technologies driving precision medicine forward.

We invite original research articles, reviews, case reports, clinical perspectives, and translational pipeline reports exploring, but not limited to:
• The latest theranostic devices and approaches in a broad range of tumor types (including gynecologic, breast, prostate, GI, and others).
• Advances in radiopharmaceutical agents for precision imaging and therapy.
• Development and application of antibody-drug conjugates and molecularly targeted payloads.
• Integration of energy oncology and targeted radiation delivery systems.
• Mechanisms of tumor targeting, resistance, efficacy, and toxicity mitigation.
• Preclinical models and translational insights illuminating novel payload strategies.
• Emerging data from clinical trials and translational programs.
• Opportunities/challenges in combining multi-modal payloads or integrating theranostics into precision oncology pathways.
• Regulatory and technological advances impacting the clinical translation of these agents.

Our aim is to provide an interdisciplinary forum for oncologists, nuclear medicine specialists, radiologists, basic scientists, and engineers to advance the application of theranostics, radiopharmaceuticals, and molecular payloads for improved cancer outcomes.

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Disclaimer: Topic Editor Dr. Lowell Anthony receives research support from Razyebio and Perspective Therapeutics. The other Topic Editors declare no competing interests with regard to the Research Topic subject.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Systematic Review
• Technology and Code

Keywords: Theranostics, Radiopharmaceuticals, Molecular Payloads, Precision Oncology, Targeted Therapy, Antibody-Drug Conjugates (ADCs), Molecular Imaging, Drug Delivery, Translational Oncology, Clinical Trials

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.